State of the Union: CAR T Cell Therapy

State of the Union: CAR T Cell Therapy

State of the Union: CAR T Cell Therapy

CAR T cell therapies are providing deep and durable remission for some patients with MM. Tune in to find out how they fit into the treatment paradigm!

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Larry Anderson, MD, PhD
    Associate Professor
    UT Southwestern Medical Center
    Dallas, TX

    Research: AbbVie, Celgene/BMS, GSK, Janssen
    Consulting Fees: AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Prothena

    Thomas G. Martin, MD
    Clinical Professor of Medicine
    UCSF Medical Center
    San Francisco, CA

    Research: Amgen, Johnson & Johnson/Janssen, Sanofi, Seattle Genetics
    Consulting Fees: GlaxoSmithKline, Oncopeptides

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Sara R. Fagerlie, PHD, CHCP has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report
    • Colleen Resnick has nothing to disclose
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Discuss current and emerging clinical trial data on CAR T cell therapies for hematologic malignancies
    2. Evaluate the access of patients with hematologic malignances to available CAR T cell therapies
  • Target Audience

    This activity is designed to meet the educational needs of hematologists, oncologists, MDs, and other healthcare professionals who manage patients with hematologic malignancies.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free